Impax Laboratories News

A A A' Product Pipeline Review A A A' H2 2011 - a new company profile report on companiesandmarkets.com IMPAX Laboratories, Inc.

Impax Laboratories was upgraded by Zacks Investment Research from an "underperform" rating to a "neutral" rating in a research report issued to clients and investors on Friday.

Impax Laboratories provides an update on a warning letter it received about its Hayward facility.

HAYWARD, Calif.-- --Feb 9, 2012 - Impax Laboratories, Inc. today provided an update on the status of its resolution of the previously disclosed warning letter issued by the U.S. Food and Drug Administration covering its Hayward manufacturing facility.

Mylan Inc said it got U.S. regulatory approval to market a generic version of Warner-Chilcott's antibiotic Doryx, finishing ahead of Impax Laboratories Inc in a race to launch the copycat version.

Hayward-based Impax Laboratories has bought the U.S. rights to AstraZeneca migraine headache drug Zomig, a deal that caused Impax's stock to rocket 7.5 percent higher Thursday.

Impax Laboratories 's stock had its "buy" rating reaffirmed by Canaccord Genuity in a research note issued on Thursday.

Dendreon Corporation A names board member John Johnson as its president and Chief Executive Officer, beginning June 30.

COCO Corinthian Colleges, Inc. Shares in the for-profit provider of post-secondary, career-oriented education programs increased as much as 44.2% to an intraday high of $4.37 at the start of the session after the Company's full-year 2012 earnings forecast of $0.30 a share beat average analyst expectations of $0.24 a share.

The SPDR S&P Pharmaceuticals ETF is seeing unusually high volume in afternoon trading Wednesday, with over 213,000 shares traded versus three month average volume of about 65,000. Shares of XPH were up about 1.8% on the day.

HAYWARD, Calif.-- -- Impax Pharmaceuticals, the branded products business unit of Impax Laboratories, Inc.

Impax Laboratories said it has licensed AstraZeneca's migraine treatment, Zomig, in the United States and will pay quarterly payments totaling $130 million during 2012 to the British drugmaker.

Perrigo Company recently announced that it has filed an application to manufacture a generic version of Meda Pharmaceuticals' Astepro nasal spray to treat nasal symptoms caused by seasonal allergies or environmental irritants.

Impax Laboratories, Inc. announced today that its fourth quarter and full year 2011 financial results will be released before the market opens on Tuesday, February 28, 2012 and will be available on Impax's Web site at www.impaxlabs.com . The Company will host a conference call and live webcast with financial analysts at 11:00 a.m., Eastern Time.

Perrigo Company Confirms Filing for Generic Version of Astepro Nasal Spray and Announcement of Patent Infringement Lawsuit by Meda Pharmaceuticals /PRNewswire/ -- Perrigo Company announced that it has filed with the U.S. Food and Drug Administration an Abbreviated New Drug Application for azelastine hydrochloride nasal spray and has notified Meda ... (more)

Impax Laboratories was downgraded by Zacks Investment Research from a "neutral" rating to an "underperform" rating in a report issued on Saturday.

Shire recently entered into an agreement with Prasco Laboratories, a US based privately held generics company.